Generic formulation development, explained
Short technical notes on the work behind a Lawsone dossier: how a marketed product's formulation gets reconstructed, what a dossier actually contains, how dissolution similarity and virtual bioequivalence are used, and what makes some formulations hard to copy. Written for formulation scientists and BD teams, not for search engines.
The notes / all public
Master formula, manufacturing procedure, specifications, equivalence evidence - what each part is, what regulators and licensees actually check, and how a dossier shortens ANDA and 505(b)(2) development.
How a candidate formula is reconstructed from public regulatory records, labeling, excipient databases, and literature - and why every figure needs a provenance tag instead of blind confidence.
What the f2 statistic measures, why regulators expect 50 or higher, what a discriminating dissolution method is, and why passing f2 in all compendial media is the first gate a candidate formula must clear.
How physiologically based pharmacokinetic (PBPK) models simulate a bioequivalence study before any human is dosed - what they can de-risk, what they cannot prove, and where they sit in a generic program.
Why poorly soluble and poorly permeable drugs need enabling technologies - amorphous solid dispersions, nanocrystal milling, lipid-based systems, and absorption enhancers - and why they are harder to copy.
Straight answers on what Lawsone sells, how dossier licensing works, what simulation can and cannot prove, and how a commission for a new molecule is scoped.